Colesevelam improved lipoprotein particle subclasses in patients with prediabetes and primary hyperlipidaemia

Author:

Goldberg Ronald B1,Rosenson Robert S2,Hernandez-Triana Eric3,Misir Soamnauth4,Jones Michael R4

Affiliation:

1. Division of Endocrinology, Diabetes and Metabolism, University of Miami Miller School of Medicine, Miami, FL, USA

2. Mount Sinai Heart, Mount Sinai School of Medicine, New York, NY, USA

3. Endocare Research Institute, Universidad del Rosario, Bogota, Colombia

4. Daiichi Sankyo, Inc., Parsippany, NJ, USA

Abstract

Background: A randomised, double-blind, placebo-controlled study evaluated lipid- and glucose-lowering effects of colesevelam in patients with prediabetes and primary hyperlipidaemia. We report the effect of colesevelam on lipoprotein particle concentration and particle size (determined by nuclear magnetic resonance spectroscopy) in these patients. Methods: Adults with prediabetes (World Health Organization criteria), low-density lipoprotein cholesterol (LDL-C) ≥ 100 mg/dL (≥2.6 mmol/L) and triglycerides < 500 mg/dL (<5.6 mmol/L) were randomised to colesevelam 3.75 g/day or placebo for 16 weeks. The intent-to-treat population comprised 103 colesevelam and 106 placebo recipients. Results: At the end of the study, mean reduction from baseline in total LDL particle concentration was significantly greater with colesevelam versus placebo (mean treatment difference: −113 nmol/L; p = 0.02). Increases in total very low-density lipoprotein particle concentration (VLDL-P) and high-density lipoprotein particle concentration (HDL-P) did not differ significantly between the groups; however, with colesevelam versus placebo, there were significantly ( p < 0.05) greater increases in large and medium VLDL-P and large HDL-P and reductions in small VLDL-P. Mean size increases were significantly greater with colesevelam for VLDL (mean treatment difference: 5.3 nm; p < 0.0001) and HDL (0.1 nm; p = 0.002). Conclusions: Colesevelam improved the overall atherogenic lipoprotein profile in adults with prediabetes and primary hyperlipidaemia, despite potentially less favourable changes in VLDL particles.

Publisher

SAGE Publications

Subject

Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Diabetes and Dyslipidemia;Diabetes and Cardiovascular Disease;2023

2. Modulation of Bile Acid Metabolism to Improve Plasma Lipid and Lipoprotein Profiles;Journal of Clinical Medicine;2021-12-21

3. Hypertension and Dyslipidemia in Patients with Pre-Diabetes;Glucose Intake and Utilization in Pre-Diabetes and Diabetes;2015

4. Nuclear bile acid signaling through the farnesoid X receptor;Cellular and Molecular Life Sciences;2014-12-16

5. Glucose-lowering effects of intestinal bile acid sequestration through enhancement of splanchnic glucose utilization;Trends in Endocrinology & Metabolism;2014-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3